Spero Therapeutics Inc.

NASDAQ: SPRO · Real-Time Price · USD
1.91
-0.07 (-3.54%)
At close: Aug 15, 2025, 2:36 PM

Spero Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
27.4M 96.73M 48.58M 18.26M
Cost of Revenue
2K 367K 1.55M 1.12M
Gross Profit
27.39M 96.37M 5.92M 17.14M
Operating Income
-73.36M 21.48M -42.2M -87.97M
Interest Income
4.74M 3.94M 1.11M 346K
Pretax Income
-68.57M 25.4M -46.41M -89.76M
Net Income
-68.57M 22.81M -46.41M -89.76M
Selling & General & Admin
23.7M 25.55M 36.48M 41.7M
Research & Development
96.76M 51.44M 47.59M 64.53M
Other Expenses
-19.7M -1.74M -35.96M -15.19M
Operating Expenses
100.76M 75.25M 48.11M 91.04M
Interest Expense
n/a n/a 2.6M 1.94M
Selling & Marketing Expenses
n/a n/a n/a n/a
Cost & Expenses
100.76M 75.25M 84.08M 106.23M
Income Tax Expense
n/a 2.6M 1.61M 1.54M
Shares Outstanding (Basic)
54.04M 52.7M 37.59M 30.9M
Shares Outstanding (Diluted)
54.04M 52.99M 37.59M 30.9M
EPS (Basic)
-1.27 0.43 -1.23 -2.91
EPS (Diluted)
-1.27 0.43 -1.23 -2.91
EBITDA
-72.48M 25.77M -42.26M -87.17M
EBIT
-72.48M 25.4M -43.81M -87.82M
Depreciation & Amortization
2K 367K 1.55M 646K